IDH1 and acute myeloid leukemia: With the advent of the hypomethylating agents (HMA), such as azacitidine and decitabine [2–4], and the HMA-based combination therapies with venetoclax [5, 6] or ivosidenib in IDH1-mutated AML [7], there have been significant advances in the therapy of older, unfit patients with AML.